Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

PARIS, FRANCE, 2 July 2024 – Ipsen announced confirmation of an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx® in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.